Khushali Jhaveri/LinkedIn
Jun 22, 2025, 09:24
Khushali Jhaveri: PROSPECT at ICML 2025 – Tirabrutinib in rrPCNSL
Khushali Jhaveri, Assistant Professor of Medicine at IU Simon Comprehensive Cancer Center, shared a post on X:
“PROSPECT: Tirabrutinib in rrPCNSL (n=48)
– ORR 67%, CR/CRu 27%
– mPFS 6.0 mo; mOS NR
– 81% of patients on steroids at baseline had sustained dose ↓; 69% fully discontinued
– Well tolerated; low Gr ≥3 tox Encouraging monotherapy option in a tough setting.”
More posts featuring Khushali Jhaveri.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 20:58
Aug 25, 2025, 20:44
Aug 25, 2025, 20:33
Aug 25, 2025, 19:54
Aug 25, 2025, 19:00
Aug 25, 2025, 17:36